Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial

The combination of dolutegravir plus rilpivirine has been studied in people with virologically suppressed HIV with no previous history of treatment failure or resistance. We investigated the potential to maintain viral suppression with dolutegravir plus rilpivirine in people with Lys103Asn mutations...

Full description

Saved in:

Bibliographic Details
Published in:	The lancet HIV Vol. 11; no. 3; pp. e156 - e166
Main Authors:	Moyle, Graeme, Assoumou, Lambert, de Castro, Nathalie, Post, Frank A, Curran, Adrian, Rusconi, Stefano, De Wit, Stephane, Stephan, Christoph, Raffi, François, Johnson, Margaret, Masia, Mar, Vera, Jaime, Jones, Bryn, Grove, Richard, Fletcher, Carl, Duffy, Annie, Morris, Kellie, Pozniak, Anton, Post, Frank, Winston, Alan, Kegg, Stephen, Waters, Laura, Orkin, Chole, Ustianowski, Andrew, Reeves, Iain, Leen, Clifford, Perry, Meghan, Portilla, Joaquin, Blanco, Jose Luis, Montejaro, Rocio, Domingo, Pere, Molina, Jean Michel, Katlama, Christine, Morlat, Philippe, Kenyon, Christopher, Puoti, Massimo, Rizzardini, Giuliano, Castagna, Antonella, Castelli, Francesco, Giacomelli, Andrea, Rockstroh, Jürgen, Esser, Stefan, Hoffmann, Christian, Mallon, Patrick
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Ltd 01-03-2024
Subjects:	Adult Anti-HIV Agents - adverse effects Anti-Retroviral Agents - therapeutic use Heterocyclic Compounds, 3-Ring - adverse effects HIV Infections - drug therapy HIV Seropositivity - drug therapy HIV-1 - genetics Humans Mutation Oxazines Pilot Projects Piperazines Pyridones Rilpivirine - adverse effects RNA - therapeutic use Treatment Outcome Viral Load
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The combination of dolutegravir plus rilpivirine has been studied in people with virologically suppressed HIV with no previous history of treatment failure or resistance. We investigated the potential to maintain viral suppression with dolutegravir plus rilpivirine in people with Lys103Asn mutations whose HIV was previously managed with other treatment regimens. In this open-label pilot trial at 32 clinical sites in seven European countries, virologically suppressed, HBsAg-negative adults aged 18 years or older with HIV-1 and Lys103Asn mutations were randomly assigned (2:1) to switch to 50 mg dolutegravir plus 25 mg rilpivirine (given as a single tablet) once daily or to continue their current antiretroviral therapy regimen (control group). After 48 weeks, participants in the control group also switched to dolutegravir plus rilpivirine. Randomisation was stratified by country, and a computer-generated randomisation list with permuted blocks within strata was used to assign participants to treatment groups. The primary endpoints were virological failure (ie, two consecutive measurements of 50 copies or more of HIV RNA per mL at least 2 weeks apart) and virological suppression (the proportion of participants with fewer than 50 copies of HIV RNA per mL) at week 48 (week 96 data will be reported separately). Analyses were done in the modified intention-to-treat population, which included all participants who received at least one dose of the study medication. This trial is registered with ClinicalTrials.gov, NCT05349838, and EudraCT, 2017-004040-38. Between Nov 5, 2018, and Dec 9, 2020, 140 participants were enrolled and randomly assigned, 95 to the dolutegravir plus rilpivirine group and 45 to the control group. Virological failure was recorded in three participants (3·2%, 95% CI 0·7 to 9·0) in the the dolutegravir plus rilpivirine group and one (2·2%, 0·1 to 11·8) in the control group. The proportion of participants in whom virological suppression was maintained at week 48 was 88·4% (80·2 to 94·1) in the dolutegravir plus rilpivirine group versus 88·9% (75·9 to 96·3) in the control group (difference –0·5, –11·7 to 10·7). Significantly more adverse events were recorded in the dolutegravir plus rilpivirine group than in the control group (234 vs 72; p=0·0034), but the proportion of participants who reported at least one adverse event was similar between groups (76 [80%] of 95 vs 33 [73%] of 45; p=0·39). The frequency of serious adverse events was low and similar between groups. Virological suppression was maintained at week 48 in most participants with Lys103Asn mutations when they switched from standard regimens to dolutegravir plus rilpivirine. The results of this pilot study, if maintained when the week 96 data are reported, support conduct of a large, well-powered trial of dolutegravir plus rilpivirine. ViiV Healthcare.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23
ISSN:	2352-3018 2352-3018
DOI:	10.1016/S2352-3018(23)00292-8